Bristol-Myers Squibb News

Bristol-Myers Squibb Analyst Ratings

BenzingaApr 18 11:03 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)

TipRanksApr 18 06:10 ET

Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58

MT NewswiresApr 12 07:37 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY) and Roche Holding AG (OtherRHHVF)

TipRanksApr 12 06:00 ET

Bristol-Myers Squibb: A Buy Rating on Undervaluation and Promising Product Portfolio

TipRanksApr 12 05:25 ET

Hold Rating on Bristol-Myers Squibb Amid Promising Yet Incomplete KarXT Schizophrenia Trial Data

TipRanksApr 10 02:18 ET

Bristol-Myers Squibb's Hold Rating: Balancing KarXT's Efficacy and Safety With Financial Uncertainties

TipRanksApr 8 05:47 ET

Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)

TipRanksApr 3 05:16 ET

BTIG Upgrades Nuvation to Buy, Cites AnHeart Acquisition

Seeking AlphaMar 26 13:37 ET

Hold Rating on Bristol-Myers Squibb Amidst NSCLC Trial Uncertainties and Pending KarXT Results

TipRanksMar 19 01:37 ET

Hold Rating on Bristol-Myers Squibb Amid Mixed Clinical Outcomes and Market Competition

TipRanksMar 18 05:15 ET

Hold Rating on Bristol-Myers Squibb Amid Concerns Over Abecma's Efficacy and Safety

TipRanksMar 14 07:16 ET

Truist Financial Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)

TipRanksMar 12 08:37 ET

Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85

MT NewswiresMar 11 13:49 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Krystal Biotech (KRYS) and Bristol-Myers Squibb (BMY)

TipRanksFeb 27 06:02 ET

UBS Cuts BioXcel to Neutral; Cites Regulatory Issues, Financing

Seeking AlphaFeb 21 11:03 ET

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Waters (WAT) and Bristol-Myers Squibb (BMY)

TipRanksFeb 7 08:30 ET

Bristol-Myers Squibb Analyst Ratings

BenzingaFeb 6 06:25 ET

Redburn Cuts Bristol-Myers Squibb Price Target to $54

InvestingFeb 6 05:12 ET

Hold Rating on Bristol-Myers Squibb Amid Balanced Growth and Execution Challenges

TipRanksFeb 5 07:58 ET